Clinical MedicineUpdated Aug 18, 2026Version v1
Reviewed milestones, validation shifts, standards, datasets, and debates linked to public evidence.
Evidence from Nature Communications indicates that Postsurgical and post-ACT ctDNA positivity are significantly associated with worse recurrence-free survival. This is tracked as a clinical because it changes how Liquid Biopsy for Early Cancer Detection is understood, validated, or applied. It is supported by 3 papers in the same timeline signal.
Evidence from Nature Communications indicates that Postsurgical and post-ACT ctDNA positivity are significantly associated with worse recurrence-free survival. This is tracked as a clinical because it changes how Liquid Biopsy for Early Cancer Detection is understood, validated, or applied. It is supported by 3 papers in the same timeline signal.
Evidence from Frontiers in Medicine indicates that NASH can lead to progressive liver fibrosis, a major prognostic predictor in NAFLD. This is tracked as a standard because it changes how Liquid Biopsy for Early Cancer Detection is understood, validated, or applied.
Evidence from Frontiers in Medicine indicates that NASH can lead to progressive liver fibrosis, a major prognostic predictor in NAFLD. This is tracked as a standard because it changes how Liquid Biopsy for Early Cancer Detection is understood, validated, or applied.
Evidence from Molecular Cancer indicates that Liquid biopsies offer a non-invasive alternative to traditional cancer diagnostic methods. This is tracked as a standard because it changes how Liquid Biopsy for Early Cancer Detection is understood, validated, or applied.
Evidence from Scientific Reports indicates that MRE-Seq achieved an AUC of 0.978 with 78.1% sensitivity and 99.2% specificity for colorectal cancer. This is tracked as a clinical because it changes how Liquid Biopsy for Early Cancer Detection is understood, validated, or applied. It is supported by 3 papers in the same timeline signal.
Evidence from Molecular Cancer indicates that Liquid biopsies offer a non-invasive alternative to traditional cancer diagnostic methods. This is tracked as a standard because it changes how Liquid Biopsy for Early Cancer Detection is understood, validated, or applied.
Evidence from Science indicates that Early detection significantly improves cancer survival. This is tracked as a clinical because it changes how Liquid Biopsy for Early Cancer Detection is understood, validated, or applied. It is supported by 2 papers in the same timeline signal.
Evidence from Science indicates that Early detection significantly improves cancer survival. This is tracked as a clinical because it changes how Liquid Biopsy for Early Cancer Detection is understood, validated, or applied. It is supported by 2 papers in the same timeline signal.
Evidence from Scientific Reports indicates that MRE-Seq achieved an AUC of 0.978 with 78.1% sensitivity and 99.2% specificity for colorectal cancer. This is tracked as a clinical because it changes how Liquid Biopsy for Early Cancer Detection is understood, validated, or applied. It is supported by 3 papers in the same timeline signal.
Evidence from Nature indicates that Preoperative ctDNA absence is a marker for indolent lung adenocarcinoma. This is tracked as a standard because it changes how Liquid Biopsy for Early Cancer Detection is understood, validated, or applied.
Evidence from Nature indicates that Preoperative ctDNA absence is a marker for indolent lung adenocarcinoma. This is tracked as a standard because it changes how Liquid Biopsy for Early Cancer Detection is understood, validated, or applied.